SMTL ID : 4hww.1 (1 other biounit)

Crystal structure of human Arginase-1 complexed with inhibitor 9

Coordinates

PDB Format

Method

X-RAY DIFFRACTION 1.30 Å

Oligo State

homo-trimer

Ligands

3 x X7A: [(5R)-5-amino-5-carboxy-7-(piperidin-1-yl)heptyl](trihydroxy)borate(1-)(Non-covalent)

X7A.1: 17 residues within 4Å: Chain A: H.97, D.120, H.122, D.124, N.126, T.132, S.133, H.137, G.138, D.179, E.182, D.228, D.230, T.242, E.273 Ligands: MN.2, MN.3 16 PLIP interactions: 16 interactions with chain A Hydrogen bonds: A:N.126, A:S.133, A:D.179, A:T.242, A:E.273 Water bridges: A:D.124, A:T.131, A:S.133, A:S.133, A:N.135, A:N.135, A:N.135, A:D.179, A:T.242, A:E.273 Salt bridges: A:D.179 X7A.4: 17 residues within 4Å: Chain B: H.97, D.120, H.122, D.124, N.126, T.132, S.133, H.137, G.138, D.179, E.182, D.228, D.230, T.242, E.273 Ligands: MN.5, MN.6 16 PLIP interactions: 16 interactions with chain B Hydrogen bonds: B:N.126, B:S.133, B:D.179, B:T.242, B:E.273 Water bridges: B:D.124, B:T.131, B:S.133, B:S.133, B:N.135, B:N.135, B:N.135, B:D.179, B:T.242, B:E.273 Salt bridges: B:D.179 X7A.7: 17 residues within 4Å: Chain C: H.97, D.120, H.122, D.124, N.126, T.132, S.133, H.137, G.138, D.179, E.182, D.228, D.230, T.242, E.273 Ligands: MN.8, MN.9 16 PLIP interactions: 16 interactions with chain C Hydrogen bonds: C:N.126, C:S.133, C:D.179, C:T.242, C:E.273 Water bridges: C:D.124, C:T.131, C:S.133, C:S.133, C:N.135, C:N.135, C:N.135, C:D.179, C:T.242, C:E.273 Salt bridges: C:D.179

6 x MN: MANGANESE (II) ION(Non-covalent)

MN.2: 6 residues within 4Å: Chain A: D.120, H.122, D.228, D.230 Ligands: X7A.1, MN.3 5 PLIP interactions: 5 interactions with chain A Metal complexes: A:D.120, A:H.122, A:D.228, A:D.230, A:D.230 MN.3: 6 residues within 4Å: Chain A: H.97, D.120, D.124, D.228 Ligands: X7A.1, MN.2 4 PLIP interactions: 4 interactions with chain A Metal complexes: A:H.97, A:D.120, A:D.124, A:D.228 MN.5: 6 residues within 4Å: Chain B: D.120, H.122, D.228, D.230 Ligands: X7A.4, MN.6 5 PLIP interactions: 5 interactions with chain B Metal complexes: B:D.120, B:H.122, B:D.228, B:D.230, B:D.230 MN.6: 6 residues within 4Å: Chain B: H.97, D.120, D.124, D.228 Ligands: X7A.4, MN.5 4 PLIP interactions: 4 interactions with chain B Metal complexes: B:H.97, B:D.120, B:D.124, B:D.228 MN.8: 6 residues within 4Å: Chain C: D.120, H.122, D.228, D.230 Ligands: X7A.7, MN.9 5 PLIP interactions: 5 interactions with chain C Metal complexes: C:D.120, C:H.122, C:D.228, C:D.230, C:D.230 MN.9: 6 residues within 4Å: Chain C: H.97, D.120, D.124, D.228 Ligands: X7A.7, MN.8 4 PLIP interactions: 4 interactions with chain C Metal complexes: C:H.97, C:D.120, C:D.124, C:D.228

Links

RCSB   PDBe   PDBe-KB   PDBj   PDBsum   CATH   PLIP

Citation

Van Zandt, M.C. et al., Discovery of (R)-2-Amino-6-borono-2-(2-(piperidin-1-yl)ethyl)hexanoic Acid and Congeners As Highly Potent Inhibitors of Human Arginases I and II for Treatment of Myocardial Reperfusion Injury. J.Med.Chem. (2013)

Release Date

2013-03-20

Peptides

Arginase-1: ABC

SMTL:PDB

SMTL Chain Id:
PDB Chain Id:

A
A

B
A

C
A

Arginase-1

Related Entries With Identical Sequence